KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBIT Margin (2016 - 2025)

Fulgent Genetics' EBIT Margin history spans 11 years, with the latest figure at 48.18% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 6935.0% year-over-year to 48.18%; the TTM value through Dec 2025 reached 4.56%, up 2152.0%, while the annual FY2025 figure was 4.56%, 2152.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 48.18% at Fulgent Genetics, up from 18.26% in the prior quarter.
  • Across five years, EBIT Margin topped out at 74.26% in Q1 2021 and bottomed at 214.34% in Q4 2023.
  • The 5-year median for EBIT Margin is 19.71% (2024), against an average of 5.96%.
  • The largest annual shift saw EBIT Margin crashed -16035bps in 2023 before it surged 19317bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 59.94% in 2021, then crashed by -190bps to 53.99% in 2022, then tumbled by -297bps to 214.34% in 2023, then soared by 90bps to 21.17% in 2024, then skyrocketed by 328bps to 48.18% in 2025.
  • Per Business Quant, the three most recent readings for FLGT's EBIT Margin are 48.18% (Q4 2025), 18.26% (Q3 2025), and 24.1% (Q2 2025).